ITEM METADATA RECORD
Title: Neutralization of membrane TNF, but not soluble TNF, is crucial for the treatment of experimental colitis
Authors: Perrier, Clémentine
De Hertogh, Gert
Cremer, Jonathan
Vermeire, Severine
Rutgeerts, Paul
Van Assche, Gert
Szymkowski, David E
Ceuppens, Jan L # ×
Issue Date: Feb-2013
Publisher: John Wiley & Sons
Series Title: Inflammatory bowel diseases vol:19 issue:2 pages:246-53
Article number: 10.1002/ibd.23023
Abstract: BACKGROUND: Agents neutralizing membrane tumor necrosis factor (mTNF) and soluble TNF (sTNF) are widely used for the treatment of inflammatory bowel disease (IBD). Neutralization of mTNF, however, is associated with increased susceptibility to infectious diseases. The aim of this study was to determine whether neutralization of sTNF exclusively, by the use of a dominant negative mutant of TNF (XENP1595), could reduce the severity of colitis in mice. METHODS: Colitis was induced in immunodeficient mice by transfer of CD45RB(hi) CD25(-) T-cells. Once the disease had developed, mice were treated twice a week with XENP1595, phosphate-buffered saline (PBS), anti-TNF monoclonal antibody (mAb), or isotype control. The anti-TNF mAb blocks both mTNF and sTNF. Weights, disease activity index, macroscopic inflammation of the colon, and histological sections were evaluated. T-cell populations from the colon were analyzed by flow cytometry. RESULTS: Treatment of mice with XENP1595 did not change the course of the disease, whereas mice treated with anti-TNF mAb recovered weight soon after the first treatment dose. Inflammation in the colon was reduced in mice treated with anti-TNF mAb compared to isotype control-treated animals. Mice treated with XENP1595 had a similar degree of inflammation in the colon as PBS-treated animals. The number of effector and regulatory T-cells in the colon remained unaffected by all treatments. CONCLUSIONS: Neutralization of sTNF exclusively was unable to induce remission in T-cell-mediated colitis, suggesting that neutralization of mTNF is crucial for the treatment of IBD. (Inflamm Bowel Dis 2012;).
URI: 
ISSN: 1078-0998
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Translational Cell & Tissue Research
Laboratory of Clinical Immunology
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

 


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science